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Renal revascularization by percutaneous transluminal
angioplasty improves blood pressure and stenotic kidney
function in selected groups of patients, but the reversibility
of intrarenal and microvascular remodeling remains
unknown. Here, we tested the hypothesis that renal
angioplasty improves the function and structure of renal
microcirculation in experimental chronic renal artery stenosis.
Stenotic kidney function, hemodynamics, and endothelial
function were assessed in vivo in pigs after 10 weeks of
unilateral renal artery stenosis. Renal microvascular
remodeling, angiogenic pathways, and fibrosis were
measured ex vivo. Angioplasty and stenting carried out
4 weeks before measurement decreased blood pressure,
improved glomerular filtration rate, and improved
microvascular endothelial function. It also promoted the
expression of angiogenic factors and decreased renal
apoptosis due to stenosis, compared with a sham
intervention. The spatial density of renal microvessels,
however, was partially improved after angioplasty. Renal
blood flow was incompletely restored compared with the
kidneys of sham-treated animals, as was interstitial fibrosis.
Renal microvascular media-to-lumen ratio remained
unchanged by angioplasty. Thus, our study shows that
revascularization of a stenotic renal artery restores the
glomerular filtration rate and renal endothelial function
4 weeks later. Renal hemodynamics and structure, however,
are incompletely resolved.
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Renal artery stenosis (RAS) induced mainly by atheromatous
disease can accelerate hypertension and renal failure1 and
lead to adverse cardiovascular outcomes. The main treatment
options for RAS include medical therapy and/or revasculari-
zation of the stenotic renal artery aimed to improve blood
pressure control and preserve renal function.
The role of percutaneous transluminal renal angioplasty
(PTRA), followed by stenting of the revascularized renal
artery and optimal medical therapy, remains controversial.
Although restoration of kidney perfusion should restore renal
function and improve blood pressure control, several
prospective, randomized trials up to now fail to identify
compelling benefits for cardiovascular or kidney outcomes.2
Notably, most studies in humans evaluating the response
to PTRA are limited to changes in serum creatinine,
glomerular filtration rate (GFR), blood pressure, or number
of medications.3,4
Obstruction of flow in the renal artery initiates a complex
cascade of events that remains incompletely understood.
Using a swine model of progressive RAS, we have previously
shown that the kidney exposed to chronic RAS shows
functional deterioration accompanied by renal inflammation,
fibrosis, and microvascular rarefaction and remodeling.5–8
Diminished intrarenal microvascular density may be the
result of either altered or insufficient angiogenesis with or
without acceleration of apoptosis. It is associated with
impaired renal function and structure.8 However, little is
known about the ability of revascularization to restore the
renal microcirculation and attenuate microvascular injury.
The aims of this study were to explore the effect of
PTRA and stenting on intrarenal microvascular remodeling,
angiogenesis, and fibrosis. To test the hypothesis that
PTRA can modify the function and structure of renal
microcirculation in the stenotic kidney, we used a large
animal model of chronic experimental RAS. The pigs
underwent revascularization with PTRA and stenting
after 6 weeks of unilateral RAS, a duration associated with
the development of renovascular hypertension, kidney
dysfunction, and renal fibrosis.9–11 They were studied in vivo
4 weeks later, to allow for detectable improvement of renal
and endothelial functions.12,13
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RESULTS
Systemic and hemodynamic parameters
At 6 weeks after coil implantation, hemodynamically
significant RAS (460%) was present in all pigs (Figure 1a
and b). PTRA was successfully performed in six pigs (degree
of stenosis before PTRA 68.3±4.4%) and was followed by
a decrease of mean arterial pressure (MAP) to the baseline
level (Figure 1c), whereas the remaining RAS pigs (degree
of stenosis 71.5±6.3%, P¼NS) had sham angiography.
Sham-treated RAS group still had significant stenosis
(75.3±5.9%) and elevated systolic blood pressure (Po0.05
vs sham) 4 weeks later, and MAP tended to increase as well
(P¼ 0.068), whereas in RASþ PTRA group the renal artery
was patent with a minimal residual stenosis (Table 1). Blood
pressure after PTRAwas lower than untreated RAS group and
not different from sham-treated group (Table 1). Creatinine
levels slightly increased in RAS group and were lower after
PTRA, whereas plasma renin activity was not different among
the groups (Table 1).
Renal hemodynamics and function
At 10 weeks after induction of RAS, basal GFR and renal
blood flow (RBF) were significantly lower in the RAS kidney
compared with sham and the response to acetylcholine
(Ach) was attenuated (Figure 1d), indicating endothelial
dysfunction. In the RASþ PTRA group, GFR was improved
and not different from sham, whereas RBF was not
significantly higher than RAS and remained lower compared
with sham (Po0.05). Nevertheless, both GFR and RBF
responses to Ach were improved (P¼ 0.016 and P¼ 0.001 vs
baseline, respectively), suggesting an improvement of en-
dothelial function after PTRA. The slight decrease in renal
volume in RAS was partially reversed by PTRA, but this did
not reach statistical significance because of a high variability
(Table 1). Cortical perfusion, which tended to decrease in
RAS, reached statistical significance in RASþ PTRA group
(Po0.01 vs sham, Table 1) and was not different between the
two RAS groups.
Microvascular three-dimensional architecture and
remodeling
Overall, transmural spatial density of renal microvessels
across the cortical regions was lower in RAS (Po0.01 vs
sham) and improved in RASþ PTRA (Table 2, Figure 2a and
b, P40.05 vs sham), whereas average vessel diameter was
unchanged (P¼ 0.7). Microvascular tortuousity tended to
increase in both RAS and RASþ PTRA (P¼ 0.12), suggesting
angiogenic activity to restore microvessels (Table 2). In
addition, small microvessels with a diameter under 40 mm
were reduced in RAS (Po0.001 vs sham) and improved by
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Figure 1 | Effect of PTRA on blood pressure and renal function. Renal angiography in a pig with renal artery stenosis (RAS) before
(a) and 4 weeks after (b) revascularization with percutaneous transluminal renal angioplasty (PTRA) and stenting. Arrows indicate the location
of the stenosis before and after PTRA. (c) Representative evolution of mean arterial pressure measured using telemetry in a RAS pig after
implantation of a local-irritant coil. RAS increased blood pressure, which rapidly returned to baseline levels after PTRA. (d) Single-kidney renal
blood flow (RBF) and glomerular filtration rate (GFR) at baseline (Bsl) and in response to acetylcholine (Ach). *Po0.05 vs sham, cPo0.05 vs Bsl.
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PTRA (P40.05 vs sham). The density of 40–100 mm
microvessels tended to be reduced in RAS and RASþ PTRA
(P¼ 0.073 vs sham), whereas larger microvessels were
unaffected in either group (Figure 2).
The expression of vascular endothelial growth factor
(VEGF) (Po0.05 vs sham) and Flt-1 (Po0.05 vs sham)
increased in RAS, and Flk-1 tended to increase as well
(P¼ 0.1, Figure 3). In RASþ PTRA, VEGF increased further
(Po0.01 vs RAS), whereas Flt-1 and Flk-1 both decreased to
normal levels (Figure 3). In addition, angiopoietin-1 expres-
sion was upregulated after PTRA (Po0.01 vs RAS, Figure 3),
whereas endothelial nitric oxide synthase was unchanged.
Moreover, matrix metalloproteinase-2 was increased in RAS
(Po0.05 vs sham, Figure 3), but further elevated in
RASþ PTRA (Po0.001 vs RAS, Figure 3), whereas the
expression of its inhibitor, tissue inhibitors of metalloprotei-
nase 2 (TIMP-2), was similarly blunted in both groups
(Po0.01 vs sham). The expression of tissue transglutaminase
in RAS and RASþ PTRA groups was not significantly
different from sham (P¼ 0.18, Figure 3). Increase in
microvascular media-to-lumen ratio in RAS and RASþ
PTRA groups compared with sham (Po0.001 vs sham)
indicated microvascular remodeling that was not reversed
4 weeks after PTRA (Figure 4).
Renal tissue remodeling
Renal artery stenosis showed increased renal apoptosis
(fraction of terminal deoxynucleotidyl transferase dUTP nick
end labeling (TUNEL)-positive cells) compared with sham
(Po0.01, Figure 5), in association with increased expression
of activated caspase-3. Both indices of apoptosis were
significantly attenuated after PTRA, although activated
caspase-3 expression remained higher than that in sham
(Figure 5).
In addition, trichrome staining (indicating renal fibrosis)
increased in RAS (Po0.01 vs sham, Figure 6), and was
unaffected by PTRA (Po0.05 vs sham, Figure 6). Moreover,
cortical hydroxyproline content, reflecting collagen content,
was elevated in the RAS group (16.4±3.6 vs 5.3±0.8mg per
10mg, P¼ 0.01 vs sham), and decreased but not normalized
after PTRA (8.5±0.4mg per 10mg, P¼ 0.018 vs RAS, P¼
0.002 vs sham, Figure 6). There were no detectable differences
in the expressions of transforming growth factor-b and TIMP-1
among the groups (P¼ 0.30 and P¼ 0.39, respectively,
Figure 6), but connective tissue growth factor expression
tended to increase in RAS group and was statistically
significantly elevated in RASþ PTRA group (Po0.05 vs sham,
Figure 6). The expression of xanthine oxidase increased in the
RAS kidney (Po0.05 vs sham) and decreased to sham levels
after PTRA (Po0.05 vs RAS, Figure 6), suggesting attenuation
of oxidative stress induced by RAS.
DISCUSSION
This study shows that PTRA performed after 6 weeks of
experimental RAS partially restored GFR and renal endothelial
function. These changes were associated with enhanced
proliferation and maturation of new vessels, but renal
perfusion, vascular wall remodeling, and interstitial fibrosis
remained incompletely restored. Our study therefore shows
that PTRA in swine RAS can only partially restore
the renal microcirculation. Importantly, these observations
suggest that meaningful improvement in GFR could be
achieved without complete reversal of renal tissue remodeling.
Our results extend clinical observations in human subjects
with atherosclerotic renal artery disease. Hemodynamically
significant RAS (460% decrease in luminal diameter) is
Table 1 | Systemic characteristics and basal single-kidney hemodynamics (mean±s.e.m.) in sham, sham-treated renal artery
stenosis (RAS), and RAS pigs 4 weeks after PTRA
Sham RAS RAS+PTRA
Number of kidneys 8 7 6
Body weight (kg) 47.5±1.5 56.0±3.0 54.5±3.4
Diastolic blood pressure (mm Hg) 88.3±4.0 107.6±8.3 94.5±8.1
Systolic blood pressure (mm Hg) 111.5±3.5 139.3±9.6* 122.3±10.3
Mean arterial pressure (mm Hg) 96.0±3.8 118.1±8.6 103.8±8.9
Degree of stenosis (%) 0 75.3±5.9* 5.0±3.4y
PRA (ng/ml/h) 0.25±0.04 0.22±0.05 0.25±0.14
Creatinine (mg/dl) 1.15±0.09 1.5±0.08* 1.28±0.12
Basal RBF (ml/min) 584.8±17.118 271.0±84.5* 386.1±39.5*
Basal GFR (ml/min) 70.4±2.4 32.7±10.0* 58.2±8.0
Ach-RBF (ml/min) 663.8±30.9C 334.0±106.9* 539.7±62.4C
Ach-GFR (ml/min) 91.9±2.8C 44.8±14.5* 72.4±10.6C
Renal volume (ml) 123.9±3.7 79.9±21.0 114.1±11.2
Cortical perfusion (ml/min/cc tissue) 4.96±0.11 3.85±0.43 3.78±0.23*
Abbreviations: Ach, acetylcholine; GFR, glomerular filtration rate; PRA, plasma renin activity; PTRA, percutaneous transluminal renal angioplasty; RBF, renal blood flow.
*Po0.05 vs sham; CPo0.05 vs basal values; yPo0.05 vs RAS.
Table 2 | Renal cortical microvascular architecture assessed
by micro-CT in sham, sham-treated renal artery stenosis
(RAS), and RAS+PTRA pigs
Sham RAS RAS+PTRA
Spatial density (vessels/mm2) 2.70±0.24 1.50±0.15* 1.97±0.06
Average vessel diameter (mm) 91±4 102±12 95±9
Tortuousity (ratio) 1.30±0.04 1.43±0.05 1.51±0.12
Abbreviations: micro-CT, micro-computed tomography; PTRA, percutaneous trans-
luminal renal angioplasty.
Values are means±s.e.m. *Po0.05 vs sham.
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detected in almost 7% of individuals older than 65 years of
age.14 RAS regularly accelerates renovascular hypertension,
renal dysfunction, and increased cardiovascular mortality.
Revascularization of the kidney using PTRA or other means
can lead to a decrease in blood pressure, and in turn to an
improvement in the systemic endothelial function and
oxidative stress.12 Remarkably, renal function improves only
in a minority of patients with atherosclerotic RAS.1 However,
the reasons for incomplete recovery of renal function in
RAS remain obscure.2
In our experimental swine model, arterial pressure
increased within a few days after implantation of a local-
irritant coil as a result of a significant RAS. We have
previously shown that this is associated with a decrease in
GFR and RBF,9,15 and with renal endothelial dysfunction.10,16
Plasma renin activity is not necessarily elevated, as typical for
a chronic phase of untreated renovascular hypertension,17
implicating recruitment of alternative pressor mechanisms
that maintain hypertension.1 Our current studies with
effective PTRA induced a rapid and stable decrease of arterial
pressure, and by 4 weeks after PTRA, renal function (GFR
and serum creatinine) improved as well. RBF improved
only slightly, although not significantly, but its response to
Ach was restored, suggesting improvement of endothelial
function that was impaired in RAS. Notably, the reduction in
pressure distal to RAS leads to decreased vascular tone due to
compensatory dilatation, which might attenuate the extent of
microvascular responsiveness to Ach. Hence, improved RBF
and GFR responses to Ach might be partly secondary to
restoration of basal vascular tone rather than endothelial
function. Nevertheless, the greater improvement in MAP
than RBF suggests that vascular resistance distal to the
stenosis remained elevated.
We have previously shown that deterioration of renal
hemodynamics and function in our RAS model is accom-
panied by oxidative stress, apoptosis, fibrosis, and inflamma-
tion.6,7 In the current study, we observed that 4 weeks after
PTRA, GFR and endothelial function improved, possibly
secondary to the decrease in oxidative stress, as reflected in
the downregulation of the expression of radical-producing
enzyme, xanthine oxidase, thought to have an important role
in renal ischemic injury.18 Renal cell apoptosis was also
reduced, suggesting reversal of renal ‘hibernation’16 in a
kidney with preserved regenerative capacity.19 Nevertheless,
renal fibrosis induced by RAS was only partially improved
after PTRA. As transforming growth factor-b and TIMP-1
were only slightly and not significantly upregulated by
RAS, additional pro-fibrotic factors likely mediated renal
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Figure 2 | The kidney microcirculation before and after revascularization of a stenotic renal artery. Representative three-dimensional
tomographic images of the cortical microcirculation in sham, renal artery stenosis (RAS), and RASþpercutaneous transluminal renal
angioplasty (PTRA) pigs (a) and spatial density (b, mean±s.e.m.) of different size microvessels. PTRA slightly increased intrarenal density of
small microvessels. *Po0.05 vs sham.
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fibrosis in this model. Indeed, trichrome staining and the
hydroxyproline assay showed an increase in renal collagen
content induced by RAS. Moreover, connective tissue growth
factor expression further increased after PTRA, trichrome
staining was unaffected, and collagen content was not fully
restored by PTRA, suggesting that the scarring process was
incompletely arrested and that extracellular matrix deposited
was not cleared from the kidney.
Furthermore, we have shown before that deterioration of
renal function in RAS is associated with microvascular
rarefaction and remodeling.5–8 We suggested that angiogenic
competence might be linked to renal functional recovery.5
Neovascularization involves a sequence of events, such as
endothelial cell proliferation, migration, differentiation,
remodeling of extracellular matrix, and functional matura-
tion of the newly assembled vessels, which are often mediated
by VEGF.20 Although the stenotic kidney showed elevated
expression of VEGF, microvascular density was decreased.
This might be partly due to the increased renal expression of
the VEGF receptor Flt-1, which can sequester VEGF to
decrease its activity and interfere with neovascularization.21
Interestingly, we found that PTRA led to an increase in VEGF
expression and microvascular density, especially in renal
vessels o40 mm in diameter, which was accompanied by
a slight increase of tortuousity, characteristic of angiogenic
vessels, implying enhanced angiogenic efficacy.
The PTRA-induced neovascularization was likely
mediated by interaction among several growth factors acting
in concert. A decrease in Flt-1 might have contributed to an
increase in effective VEGF availability, whereas the increase in
renal expression of angiopoietin-1 in RASþ PTRA mediated
maturation of the new vessels,22 and the interaction between
VEGF and angiopoietin-1 fostered microvascular stabiliza-
tion. Matrix metalloproteinase-2 was increased in RASþ
PTRA, and facilitated angiogenesis by degrading surrounding
extracellular matrix and allowing endothelial cell invasion.23
Taken together, our results indicate an important increase in
proangiogenic milieu in the RAS kidney after PTRA,
although with only partial restoration of the microvessels
lost in RAS. These observations suggest that augmentations
of the proangiogenic milieu in the post-stenotic kidney may
offer the potential for new vessel formation in patients
undergoing endovascular procedures.
It is important to recognize that microvascular vessel wall
remodeling was not changed after PTRA and stenting, as
indicated by the elevated media-to-lumen ratio. Moreover,
the increased fraction of TUNEL-positive renal cells in RAS
suggested increased apoptosis, as previously described,7
which was underscored by activation of caspase-3, an
important effector of apoptosis. PTRA diminished both
TUNEL staining and activated caspase-3 expression, imply-
ing attenuation of the apoptotic process by PTRA. Never-
theless, caspase-3 expression did not return to sham levels
after PTRA, both renal interstitial fibrosis and microvascular
remodeling were not restored, and neovascularization was
incomplete. This study therefore shows curtailed structural
recovery 4 weeks after PTRA, which may, in part, account for
the mere partial restoration of RBF in the stenotic kidney. In
most patients with nonatherosclerotic RAS, technically
successful PTRA is followed by a prompt decrease in blood
pressure within 1–6 h; in 93% it has stabilized within 24 h,
and remains stable at 6 months.24 Indeed, we observed that
blood pressure in RAS started decreasing shortly after PTRA.
We would expect to observe improvement in renal function
by 4 weeks after PTRA, because an increase in GFR in human
RAS has been documented within 5 days after angioplasty,13
but may occur even earlier in parallel to MAP. Furthermore, a
recent study in patients with RAS showed significant
improvement in endothelial function and a decrease in
blood pressure and oxidative stress by 1 month after
angioplasty.12 Therefore, our observation that 4 weeks after
PTRA GFR increased while RBF and the renal microcircula-
tion remained impaired, likely bears clinical relevance.
Our study was limited by the use of pigs without
comorbid conditions, and by a short duration of RAS
relative to the human disease. Human RAS is multifactorial
and particularly dependent on the severity, evolution,
and duration of the stenosis, as well as on other concur-
rent or preexisting pathophysiological conditions such as
essential hypertension, diabetes, or hypercholesterolemia,
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Figure 3 | Immunoblots (upper panel) and densitometric
quantification (bottom) showing renal protein expression of
vascular endothelial growth factor (VEGF), Flt-1, Flk-1,
angiopoietin-1, endothelial nitric oxide synthase (eNOS),
pro-matrix metalloproteinase (MMP)-2, tissue inhibitors of
metalloproteinase 2 (TIMP-2) and tissue transglutaminase
(tTG) in sham, renal artery stenosis (RAS), and
RASþpercutaneous transluminal renal angioplasty (PTRA)
groups. PTRA increased VEGF and angiopoietin-1 expression,
suggesting a proangiogenic milieu in these kidneys.
Mean±s.e.m., *Po0.05 vs sham, yPo0.05 vs RAS.
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which impair the renal microvasculature and likely modulate
its response to revascularization. Nevertheless, renal structure
and function in the swine model are similar to human
kidneys, and our results bear relevance and may shed light on
the reversibility of renal injury after revascularization.
In conclusion, the present study shows that PTRA in
chronic porcine RAS partially restored the renal microvas-
cular network and allowed GFR recovery. However, our study
suggests that the improvement in GFR and decrease in blood
pressure 4 weeks after PTRA may conceal residual structural
damage even in the post-stenotic kidney uncomplicated by
atherosclerosis. These observations suggest that the improve-
ment in renal function can precede or be achieved without
complete eradication of renal scarring. Future studies will
need to determine whether such residual damage might
resolve, interfere with renal functional reserve, or predispose
the kidney for future injury.
MATERIALS AND METHODS
Experimental protocol and multidetector computer
tomography analysis
The institutional Animal Care and Use Committee approved all the
procedures. In all, 21 female domestic pigs (45–68 kg) were studied
after 10 weeks of observation. At baseline, all the pigs were
anesthetized with an intramuscular injection of telazol (5mg/kg)
and xylazine (2mg/kg), intubated, and mechanically ventilated with
room air. Anesthesia was maintained with a mixture of ketamine
(0.2mg/kg/min) and xylazine (0.03mg/kg/min) in normal saline
(0.05 ml/kg/min). In 13 pigs, RAS was induced at baseline by a local-
irritant coil placed in the main renal artery, inducing gradual
development of unilateral RAS by 5–7 days, as described pre-
viously.9,25,26 A PhysioTel telemetry system (Data Sciences Interna-
tional, Arden Hills, MN, USA) was implanted on the same day in
a femoral artery to continuously monitor MAP in all animals.25,26
MAP was recorded at 5-min intervals and averaged for each
24-h period. Levels reported in Table 1 were those obtained for
2 days preceding the in vivo studies.
At 6 weeks after induction of RAS, the pigs were anesthetized
again and randomized into two groups that underwent either sham
treatment (RAS, n¼ 7) or PTRA (RASþ PTRA, n¼ 6). The degree
of stenosis was evaluated by selective renal angiography, followed by
PTRA or sham procedure. A 7F balloon catheter was engaged in the
proximal-middle section of the renal artery under fluoroscopic
guidance and the balloon was inflated, resulting in expansion of
a tantalum stent to full balloon diameter, to restore luminal
opening. Then, the balloon was deflated and removed, leaving the
stent embedded in the vascular wall. A group of normal kidneys that
did not undergo coil implantation served as controls (sham, n¼ 8).
The pigs were again anesthetized similarly, 4 weeks later. Blood
samples were collected from the inferior vena cava for the
measurement of plasma renin activity (radio-immunoassay) and
creatinine (colorimetric assay).8 Single-kidney renal function was
then evaluated in vivo using helical multidetector computer
tomography for assessment of basal regional renal perfusion, RBF,
and GFR, as previously described in detail.5–7,27,28 Briefly, this
method was performed with sequential acquisition of 160
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Figure 4 |Microvascular remodeling in the stenotic kidney. (a) Representative renal a-smooth muscle actin staining in sham, renal artery
stenosis (RAS), and RASþpercutaneous transluminal renal angioplasty (PTRA) kidneys. (b) Quantification of media-to-lumen ratio
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consecutive scans over a period of almost 3min after a central
venous injection of iopamidol (0.5ml/kg for 2 s). Multidetector
computer tomography images were reconstructed and displayed
with the Analyze software package (Biomedical Imaging Resource,
Mayo Clinic, MN, USA). Regions of interest were selected from
cross-sectional images from the aorta, renal cortex, and medulla.
Average tissue attenuation in each region was plotted over time and
fitted by curve-fitting algorithms to obtain measures of renal
function. Cortical and medullary volumes were calculated by
Analyze (Biomedical Imaging Resource, Mayo Clinic, MN, USA)
and RBF as the sum of the products of cortical and medullary
perfusions and corresponding volumes. GFR was calculated from
the cortical curve using the slope of the proximal tubular curve. The
same procedure was repeated after 15min toward the end of a 10-
min suprarenal infusion of Ach (5mg/kg/min) to test endothelium-
dependent microvascular reactivity. Briefly, a tracker catheter
(Prowler Microcatheter, Cordis, Miami, FL, USA) introduced from
the carotid artery was placed above the renal arteries for infusion of
Ach. Hemodynamics and function were therefore measured over a
stable 3-min observation period at baseline and during Ach infusion.
Few days after completion of all functional studies, the pigs were
killed (100mg/kg sodium pentobarbital). Kidneys were removed,
immersed in 41C saline solution containing heparin (10U/ml), and
divided into different lobes, and stored at 801C by immersing
them in 10% buffered formalin, or cannulated and prepared for
micro-computed tomography analysis.
Micro-computed tomography analysis
All kidneys were perfused with 0.9% saline (containing heparin) at
10ml/min under physiological perfusion pressure (100mmHg),
using a saline-filled cannula ligated in a segmental artery. After
5–10min, this was replaced with an intravascular radio-opaque
silicone polymer (Microfil MV122; Flow Tech, Carver, MA, USA;
0.8ml/min) until the polymer drained freely from the segmental
vein. A lobe of the polymer-filled tissue was subsequently trimmed,
prepared and encased in paraffin, and scanned at 0.51 increments
using a micro-computed tomography scanner, as described
previously.8 Three-dimensional volume images were then recon-
structed at cubic voxels of 20mm on a side, and displayed at 40-mm
cubic voxels for analysis. The spatial density, average diameter, and
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Figure 5 |Apoptosis in the stenotic kidney, and response to revascularization. Caspase-3 (a, brown) and terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) (b, green) staining and quantification (c), showing increased number of positive (apoptotic
signal) cells in renal artery stenosis (RAS), which was decreased after percutaneous transluminal renal angioplasty (PTRA). *Po0.01 vs sham;
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tortuousity of cortical microvessels were calculated as we have
previously described,8,29 and classified according to diameter as small
(o40mm), medium (40–100mm), or large (4100mm) vessels.
Immunohistochemistry and western blotting
In vitro studies were performed to assess mechanisms responsible
for formation and maintenance of the renal microvasculature,
as well as fibrogenic factors and oxidative stress in the kidney.
Standard western blotting protocols were performed7 with specific
antibodies previously used or that cross-react with swine tissue. We
used antibodies against VEGF, its receptors Flt-1 and Flk-1,
angiopoietin-1, endothelial nitric oxide synthase, matrix metallo-
proteinase-2, transforming growth factor-b, TIMP-1 and TIMP-2
(1:200, Santa Cruz Biotechnology, Santa Cruz, CA, USA), and
tissue transglutaminase (1:1000, Abcam, Cambridge, MA, USA). To
assess representative mediators of oxidative stress, protein expres-
sion of xanthine oxidase (1:10,000, Chemicon International,
Temecula, CA, USA) was also evaluated. b-actin (1:3000, Sigma,
St Louis, MO, USA) was used as loading control.
Staining was performed in 5 mm paraffin slides for Masson
trichrome and a-smooth muscle actin (1:50, Sigma), or in frozen
slides for activated caspase-3 (1:200, Santa Cruz), following standard
procedures.5,27 Each representative staining was quantified semi-
automatically in 13 fields, expressed as percentage of staining of
total surface area or number of positive cells per slide. The
microvascular media-to-lumen ratio was measured in a-smooth
muscle actin-positive microvessels under 500 mm in diameter.
Apoptotic signals were characterized in renal cells with the TUNEL
method using the DeadEnd Fluorometric TUNEL system (Promega,
Madison, WI, USA), as we have previously shown.8 Apoptotic cells
were quantified in 15 fields as the fraction of TUNEL-positive nuclei
in each field.
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Figure 6 | Stenotic kidney fibrosis and oxidative stress. Representative images of trichrome (a) and quantification (b) of trichrome
and hydroxyproline (mean±s.e.m.) in sham, renal artery stenosis (RAS), and RASþpercutaneous transluminal renal angioplasty
(PTRA) groups. Immunoblots (c) and densitometric quantification (d) showing renal protein expression of transforming growth factor
(TGF)-b, connective tissue growth factor (CTGF), tissue inhibitors of metalloproteinase 1 (TIMP-1), and xanthine oxidase in sham, RAS, and
RASþ PTRA groups; mean±s.e.m., *Po0.05 vs sham, yPo0.05 vs RAS.
Kidney International (2010) 78, 1110–1118 1117
F Favreau et al.: Renal revascularization effects o r ig ina l a r t i c l e
Collagen content
The kidney cortex of each animal was used for hydroxyproline assay
as described previously.30 Briefly, the cortex was weighed, minced,
homogenized, and diluted in phosphate-buffered saline to 100mg
cortex weight per ml. Samples (100 ml) were then hydrolyzed
in 12mol/l HCl and duplicate samples analyzed by hydroxy-
proline assay.
Statistical analysis
Quantitative data are expressed as mean±s.e.m. We tested Gaussian
distribution using Kolmogorov–Smirnov test and equality of
variances with Bartlett test. Statistical comparisons among different
experimental groups or studies were subsequently performed using
one-way analysis of variance with Newman–Keuls post hoc test or
nonparametric Kruskal–Wallis one-way analysis of variance by ranks
test with Dunns post hoc test. Paired t-test was used for comparison
within groups. Statistical significance was accepted for Pp0.05.
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